These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16710335)

  • 1. Nucleation of huntingtin aggregation in cells.
    Wetzel R
    Nat Chem Biol; 2006 Jun; 2(6):297-8. PubMed ID: 16710335
    [No Abstract]   [Full Text] [Related]  

  • 2. Stochastic kinetics of intracellular huntingtin aggregate formation.
    Colby DW; Cassady JP; Lin GC; Ingram VM; Wittrup KD
    Nat Chem Biol; 2006 Jun; 2(6):319-23. PubMed ID: 16699519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradoxical aggregation versus oligomerisation properties of mutant and wild-type huntingtin fragments.
    Rubinsztein DC; Huntington JA
    Exp Neurol; 2006 Jun; 199(2):243-4. PubMed ID: 16631742
    [No Abstract]   [Full Text] [Related]  

  • 4. Huntingtin aggregates ask to be eaten.
    Thoreen CC; Sabatini DM
    Nat Genet; 2004 Jun; 36(6):553-4. PubMed ID: 15167929
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurodegenerative disease: neuron protection agency.
    Orr HT
    Nature; 2004 Oct; 431(7010):747-8. PubMed ID: 15483586
    [No Abstract]   [Full Text] [Related]  

  • 6. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein.
    Omi K; Hachiya NS; Tanaka M; Tokunaga K; Kaneko K
    Neurosci Lett; 2008 Jan; 431(1):45-50. PubMed ID: 18078716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment.
    Persichetti F; Trettel F; Huang CC; Fraefel C; Timmers HT; Gusella JF; MacDonald ME
    Neurobiol Dis; 1999 Oct; 6(5):364-75. PubMed ID: 10527804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model.
    Weiss KR; Kimura Y; Lee WC; Littleton JT
    Genetics; 2012 Feb; 190(2):581-600. PubMed ID: 22095086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for a recruitment and sequestration mechanism in Huntington's disease.
    Preisinger E; Jordan BM; Kazantsev A; Housman D
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1029-34. PubMed ID: 10434302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversing neurodegeneration: a promise unfolds.
    Orr HT; Zoghbi HY
    Cell; 2000 Mar; 101(1):1-4. PubMed ID: 10778849
    [No Abstract]   [Full Text] [Related]  

  • 11. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models.
    Ehrnhoefer DE; Duennwald M; Markovic P; Wacker JL; Engemann S; Roark M; Legleiter J; Marsh JL; Thompson LM; Lindquist S; Muchowski PJ; Wanker EE
    Hum Mol Genet; 2006 Sep; 15(18):2743-51. PubMed ID: 16893904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Huntington's disease.
    Davies S; Ramsden DB
    Mol Pathol; 2001 Dec; 54(6):409-13. PubMed ID: 11724916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid aggregate formation of the huntingtin N-terminal fragment carrying an expanded polyglutamine tract.
    Hazeki N; Nakamura K; Goto J; Kanazawa I
    Biochem Biophys Res Commun; 1999 Mar; 256(2):361-6. PubMed ID: 10079189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulator of calcineurin (RCAN1-1L) is deficient in Huntington disease and protective against mutant huntingtin toxicity in vitro.
    Ermak G; Hench KJ; Chang KT; Sachdev S; Davies KJ
    J Biol Chem; 2009 May; 284(18):11845-53. PubMed ID: 19270310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between BDNF Val66Met polymorphism and age at onset in Huntington disease.
    Alberch J; López M; Badenas C; Carrasco JL; Milà M; Muñoz E; Canals JM
    Neurology; 2005 Sep; 65(6):964-5. PubMed ID: 16186551
    [No Abstract]   [Full Text] [Related]  

  • 16. Mutant protein in Huntington disease is resistant to proteolysis in affected brain.
    Dyer RB; McMurray CT
    Nat Genet; 2001 Nov; 29(3):270-8. PubMed ID: 11600884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease.
    Petrasch-Parwez E; Nguyen HP; Löbbecke-Schumacher M; Habbes HW; Wieczorek S; Riess O; Andres KH; Dermietzel R; Von Hörsten S
    J Comp Neurol; 2007 Apr; 501(5):716-30. PubMed ID: 17299753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologically active molecules that reduce polyglutamine aggregation and toxicity.
    Desai UA; Pallos J; Ma AA; Stockwell BR; Thompson LM; Marsh JL; Diamond MI
    Hum Mol Genet; 2006 Jul; 15(13):2114-24. PubMed ID: 16720620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An intriguing new lead on Huntington's disease.
    Barinaga M
    Science; 1996 Mar; 271(5253):1233-4. PubMed ID: 8638101
    [No Abstract]   [Full Text] [Related]  

  • 20. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death.
    Arrasate M; Mitra S; Schweitzer ES; Segal MR; Finkbeiner S
    Nature; 2004 Oct; 431(7010):805-10. PubMed ID: 15483602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.